Almog Aley-Raz Presents CorNeat Vision at LSI USA '23

Transcription

Almog Aley-Raz  0:05  

Good afternoon. My name is Almog Aley-Raz and I'm the CEO and VP r&d of CorNeat Vision. I co founded CorNeat Vision seven years ago together with Dr. Gilad Levine, a close friend and a gifted of psychologist going all the way back to the garage from an executive position in a traded company. I previously manage a high tech startup from inception to an exit and let it go with over $100 million business business line which is now part of Microsoft. Kornet vision started as an artificial cornea company, but has evolved since into a platform biomaterials company. Our material technology originally developed for permanently integrating artificial lens with resident ocular tissue presents a multibillion dollar opportunity. We recently branded it as the ever matrix, it holds the future for a new era of implants. The ever matrix is the first nondegradable completely synthetic biomimetic extracellular matrix, which is essentially the skeleton of our tissue. When implanted, it practically goes under the radar of the immune system, stimulating cellular proliferation that leads to full colonization. This material practically becomes part of the tissue and it doesn't go anywhere, kind of like a metal mesh within a concrete wall. The other matrix addresses the main issue with implants and implantables, which is a foreign body response to trigger. Our immune system will work to either degrade and eventually absorbed biomaterials, or alternatively encapsulated with a granuloma. No permanent implant today truly integrates with the surrounding soft tissue. Paper matrix disruptive tissue integration capabilities were proven in over 15 Different studies, in vitro, in vivo, and now also in humans. Here you can see histological evidence from the subcontinent tablespace, demonstrating full propolis colonization and abundant color dental position within our matrix. There is no capsule formation and even capillaries, coursing the way through the material rendering is an integral part of the tissue. We observed similar results subcon subcutaneously and also under the gingiva. But there's more. Recent preclinical studies in a calvarial defect model also prove that the ever matrix can serve as an optimal membrane for guided bone regeneration. The materials features and the surprising fact that it actually integrates with the bone positions is a superior solution over degradable collagen matrices for periodontal applications. I can't emphasize enough the potential impact of this novel biomaterial on human health Kol is from seven different fields confirmed over 40 novel applications for the material. Some are game changers in life saving. Moving forward, the plan is to partner and licensed our technology to bring some of these solutions to market. The ever matrix is poised to displace the use of donor tissue and collagen scaffolds used in many types of surgeries. Use cases include physical attachments of implants, tissue, concealment of irritating implants and sensors to avoid or encapsulation. Permanent soft tissue reinforcement, and guided tissue and bone regeneration are four initial products will revolutionize the treatment in their respective indications. Each leverage the ever matrix in a different way. We estimate their combined value to exceed $1 billion in just a few years. Given the time constraints, I'll just briefly introduce them here you're more than welcome to set up a meeting with me to review their concept of operation, business potential and plan. The Chronic caper here on the left is a self integrating artificial cornea that has already returned sight to those who are cornioley blind. It is supposed to displace the use of donor tissue providing optimal vision for patients. The Cornett ever patch is a permanent tissue integrating of Thalmic matrix there will soon replace degradable donor and process tissue in ocular surface surgeries. The G Patch is on a path for FDA clearance in the second half of this year. The CorNeat G patch is a membrane for guided tissue and bone regeneration. It is superior to degradable collagen membranes, as well as to non degradable members in many aspects. It is supposed to generate a paradigm shift in Periodontology and also finally provide a robust solution for gingival recession. We already see great interest in it from the giant in the dental fields. Last is the coronation a self regulating glaucoma drainage device. It combines tissue integration with novel drainage mechanism to finally provide a reliable and predictable long lasting solution for glaucoma. A devastating chronic eye disease. Chronic ation extends minimally invasive surgery to severe refractory glaucoma patients, a segment that hasn't seen innovation in decades. I chose to share with you this example, which clearly shows why our material is superior to donor tissue and collagen scaffolds. The ever patch was used here to conceal a glaucoma shunt. This first patient in Canada underwent a two shot implementations in both eyes in the same session. This is two months post op. As you can see here, the eye with the cornea ever patch is quiet, while the other eye with donor tissue is congested and inflame. Besides the huge aesthetic difference are key advantages of her permanency. The scleral patch will eventually get absorbed, leading to complications in some cases. All surgeons that experienced working with a coordinate every patch just loved it. It's flexible it durable, doesn't rip when sutured and provide an aesthetic solution or it is partly translucent when wet is only 100 microns in thickness, and it doesn't degrade a perfect solution for the eyewall. The CorNeat KPro artificial cornea enables cornea the blind patients around the world to fully rehabilitate their vision following a simple and straightforward procedure without reliance on donor tissue. In January 2020, we hit a major milestone with our first inhuman implantation. Jamal, a terminally blind 78 year old man who previously failed for transplantations and didn't see for a decade, regained his sight and independence following a one hour surgery. Jamal is now two years post op and since the bandages were removed, his vision is stable with no complaints on pain or discomfort. So far, we raise $16 million. In addition, we were awarded $7 million of grant money from the EU, the US Navy and the US Army of which 5.5 million are still to be collected. We are here seeking a lead investor to augment that with an $8 million round, which will allow us to launch our first two products to market complete the clinical trial for artificial Cornea toward 510K clearance. An issue is a first in human study for Game Changing glaucoma device, we will begin generating revenues through well defined use of proceeds. The funding thoughts sought will generate a set of value setting milestones and prove our platform technology for several use cases. Chronic visions versatile technology creates optionality, Evergreen value creation and risk mitigation, which will position it as an IPO candidate within a few years. Along the way. We have optionality in terms of liquidating and divesting assets in the materials dentals and atomic space. Once resources are available, we plan to further expand our portfolio possibly involve being strategic in evaluating additional game changing applications. We have a very devoted skilled and efficient team, which includes engineers, clinical regulatory and business experts. We will be opening our US Operations later this year. And we'll be fortifying our human resources with local with local talent as we enter the market. From a scientific perspective, we are supported by the world's top physicians. This includes current and past presidents of leading scientific societies. If you're interested in learning more about our products and investment opportunity, you're more than welcome to meet me while here. Thank you